

Selexis Signs Commercial License Agreement with GANYMED Pharmaceuticals

**GANYMED Pharmaceuticals AG Enters into License Agreement with Selexis SA to Use
SURE Technology PlatformSM for Mammalian Cell Line Development and for Large Scale Production of
Ganymed's First Monoclonal Antibody Drug.**

GENEVA, SWITZERLAND, July 11, 2007/PRNewswire/ -- Selexis SA, a Swiss-based biotechnology company offering technologies and services to enable significantly improved drug discovery, development, and cGMP production, announced today that it has signed a commercial license agreement with GANYMED Pharmaceuticals AG, a privately held cancer antibody company of Mainz, Germany, for use of the Selexis technology for large scale production of GANYMED's lead antibodies. Ganymed's antibodies have a unique specificity for a variety of solid cancers with high medical need and large market potential.

This commercial license agreement allows GANYMED to use a high performance cell line, developed by GANYMED scientists using the Selexis SURE Cell Line Development platform, for the clinical and commercial production of a number of products.

"We are thrilled to be extending and possibly intensifying our relationship with GANYMED Pharmaceuticals. I am also very pleased that our technology platform is supporting GANYMEDs' potent therapeutic program" said Dr. Igor Fisch, CEO of Selexis.

About Selexis:

Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services that enables significant improvements in the time, effort and costs required to develop and maintain high performance mammalian cell lines for use in the expression of pharmaceutically relevant proteins (i.e. targets, MABs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of enabling genetic elements that control the dynamic organization of chromatin within all mammalian cells. Application of the **Selexis Genetic Elements**TM using the **SURE Cell Line Development** process has enabled the rapid development of high performance cell lines for a number of pharmaceutically important programs. The Selexis core technologies also enable applications in the emerging biotechnology area of gene and stem cell therapy.

Selexis Genetic ElementsTM and SURE Cell Line DevelopmentSM are trademarks of Selexis SA.

MORE INFORMATION:

EUROPE

Igor Fisch, Ph.D.
41 (0)22 308 93 60
igor.fisch@selexis.com

UNITED STATES

Andrew F. Sanford
(617) 595-5769
andrew.sanford@selexis.com